<div id="readability-page-1"><p>Sarasin &amp; Partners LLP raised its position in shares of  CME Group Inc. (NASDAQ:CME - Free Report) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor  owned 1,125,245 shares of the financial services provider's stock after purchasing an additional 110,373 shares during the quarter. CME Group comprises  3.0% of Sarasin &amp; Partners LLP's portfolio, making the stock its 11th largest holding. Sarasin &amp; Partners LLP owned about 0.31% of CME Group worth $306,337,000 at the end of the most recent reporting period.</p><ul><li>Capitalize on Volatility: 3 Finance Stocks Thriving in 2025</li></ul><p>Several other hedge funds also recently modified their holdings of the company. Norges Bank bought a new position in  CME Group during the second quarter valued at about $1,571,447,000.  Alliancebernstein L.P. lifted its holdings in  CME Group by 185.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,244,608 shares of the financial services provider's stock valued at $330,182,000 after acquiring an additional 808,740 shares during the last quarter.  Viking Global Investors LP bought a new position in shares of  CME Group during the 2nd quarter valued at about $164,648,000.  Vanguard Group Inc. grew its stake in shares of  CME Group by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 35,176,376 shares of the financial services provider's stock worth $9,695,313,000 after purchasing an additional 532,549 shares during the last quarter.  Finally, Magellan Asset Management Ltd grew its stake in shares of  CME Group by 131,625.5% in the 2nd quarter. Magellan Asset Management Ltd now owns 486,067 shares of the financial services provider's stock worth $133,970,000 after purchasing an additional 485,698 shares during the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Ratings Changes</h2><p>CME has been the subject of a number of research reports. Citigroup upgraded shares of CME Group from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their target price for the stock from $275.00 to $300.00 in a report on Thursday, September 25th. Raymond James Financial reduced their price objective on CME Group from $309.00 to $307.00 and set an &#34;outperform&#34; rating for the company in a research note on Monday, October 13th. Morgan Stanley lifted their target price on CME Group from $312.00 to $314.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 23rd. Argus reduced their target price on CME Group from $308.00 to $295.00 in a report on Friday, October 31st. Finally, UBS Group dropped their price target on CME Group from $285.00 to $280.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, October 23rd. Eight equities research analysts have rated the stock with a Buy rating, seven have assigned  a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $290.47.</p><ul><li>Morgan Stanley: 3 Financial Stocks That Will Thrive in Volatility</li></ul><p><b>Get Our Latest Report on CME</b></p><h2>Insider Buying and Selling at CME Group</h2><p>In related news, CEO Terrence A. Duffy sold 25,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $269.55, for a total transaction of $6,738,750.00. Following the completion of the sale, the chief executive officer directly owned 65,804 shares in the company, valued at approximately $17,737,468.20. This trade represents a 27.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director William R. Shepard bought 262 shares of the stock in a transaction on Thursday, September 25th. The stock was purchased at an average price of $265.19 per share, for a total transaction of $69,479.78. Following the purchase, the director directly owned 258,459 shares of the company's stock, valued at approximately $68,540,742.21. This represents a 0.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own  0.30% of the company's stock. </p><h2>CME Group Stock Performance</h2><ul><li>4 Stocks Planning to Return Capital With Hefty Buyback Programs</li></ul><p>Shares of CME stock opened at $269.09 on Friday. The company has a market capitalization of $97.03 billion, a price-to-earnings ratio of 26.07, a P/E/G ratio of 4.02 and a beta of 0.28. CME Group Inc. has a 1-year low of $224.62 and a 1-year high of $290.79. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock's fifty day simple moving average is $272.32 and its 200-day simple moving average is $271.77. </p><p>CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The financial services provider reported $2.68 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.05. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.56 billion. CME Group had a return on equity of 14.61% and a net margin of 58.84%.The business's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period last year, the company posted $2.68 EPS.  On average, sell-side analysts predict that  CME Group Inc. will post 10.49 earnings per share for the current fiscal year. </p><h2>CME Group Dividend Announcement</h2><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Friday, December 12th will be given a $1.25 dividend. The ex-dividend date is Friday, December 12th. This represents a $5.00 dividend on an annualized basis and a yield of 1.9%. CME Group's dividend payout ratio  is presently 48.45%. </p><h2>About CME Group</h2> (Free Report)<p>CME Group Inc is a global markets company that operates some of the world's largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.  </p><p>The company's core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than CME Group</li><li>High Dividend REITs: Are They an Ideal Way to Diversify?</li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>The How And Why of Investing in Oil Stocks</li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><strong>Want to see what other hedge funds are holding CME?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01F?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01F"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CME Group Right Now?</h2><p>Before you consider CME Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.</p><p>While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Sarasin & Partners LLP increased its stake in CME Group Inc. by 10.9% in Q3, owning 1,125,245 shares worth $306,337,000. CME Group is the 11th largest holding in their portfolio. Other institutional investors also modified their holdings. Analyst ratings for CME Group vary, with a consensus rating of "Hold" and a target price of $290.47. CEO Terrence A. Duffy sold 25,000 shares, while Director William R. Shepard bought 262 shares. CME stock opened at $269.09, with a market cap of $97.03 billion.</p>

CME Group Inc. $CME Shares Acquired by Sarasin & Partners LLP